Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human parainfluenza virus 3 (HPIV-3) proteins are the structural and functional components of the HPIV-3 virion, which is a major cause of lower respiratory tract infections such as bronchiolitis and pneumonia in infants and immunocompromised individuals [1, 18, 22]. The viral genome encodes six primary structural proteins: the nucleocapsid (N) protein, phosphoprotein (P), matrix (M) protein, fusion (F) protein, hemagglutinin-neuraminidase (HN) protein, and the large (L) polymerase protein [1, 19, 22]. Among these, the HN and F surface glycoproteins are the most significant therapeutic targets; HN mediates viral attachment to host sialic acid receptors and possesses neuraminidase activity for viral release, while the F protein facilitates the fusion of the viral envelope with the host cell membrane [4, 13, 15, 21]. Currently, there are no FDA-approved vaccines or specific antivirals for HPIV-3, although several candidates like zanamivir and suramin have been studied for their ability to inhibit HN activity [2, 10, 18]. Other experimental approaches include host-directed therapies like DAS181, which removes the sialic acid receptors required for viral entry, and the development of monoclonal antibodies or T-cell therapies targeting the M or F proteins [4, 5, 23]. The replication complex, consisting of N, P, and L proteins, is also a potential target for inhibitors of viral RNA synthesis [1, 22]. Resistance to potential therapies can arise through mutations in the HN or F proteins, which may alter receptor binding or fusion efficiency [23]. Overall, targeting HPIV-3 proteins remains a critical area of research to address the significant morbidity and mortality associated with this virus in vulnerable populations [18, 23].
Neuraminidase inhibition, viral attachment inhibition, fusion inhibition, viral replication inhibition, and host receptor depletion
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human parainfluenza virus 3 protein (HPIV-3 protein).